Search
Rimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Miglustat
go.drugbank.com/drugs/DB00419ApprovedInvestigationalMiglustat was first developed as an anti-HIV agent in the 1990s. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.
Synonyms: N-(n-Butyl)deoxynojirimycin, N-ButylmoranolineMargetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … produced in Chinese Hamster Ovary (CHO) culture.
Probucol
go.drugbank.com/drugs/DB01599ApprovedInvestigationalWithdrawnA drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
Categories: Compounds used in a research, industrial, or household settingMethyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A232224] First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. … [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects.
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … fragment C5a and its cognate C5aR receptor in AAV.
Pirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnIn vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. … in a concentration between 10-50%.
Categories: Compounds used in a research, industrial, or household settingBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and Fim3).
Mixtures: Repevax Injektionssuspension in einer Fertigspritze, Covaxis Injektionssuspension in einer FertigspritzePlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigationalSince CXCR4 and SDF-1α are involved in the trafficking and homing of CD34+ cells to the marrow compartment, blocking this interaction leads to an increase in CD34+ cell circulating levels. … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678]